• (-)-Arctigenin as a MEK1 Inhibitor: Practical Oncology Workf

  2026-04-27

  (-)-Arctigenin unlocks precise manipulation of NF-κB and MEK1 pathways, enabling advanced anti-inflammatory and anti-metastatic research in breast cancer models. This guide translates cutting-edge discoveries into optimized protocols and actionable troubleshooting tips, empowering researchers to harness the full potential of this high-purity small molecule.

• Aconitase Activity Colorimetric Assay Kit: Applied Workflows

  2026-04-27

  The Aconitase Activity Colorimetric Assay Kit empowers researchers to quantify iron-sulfur protein aconitase activity with speed and sensitivity, crucial for metabolic and oxidative stress studies. Explore hands-on protocols, advanced applications, and troubleshooting strategies that set this tool apart in TCA cycle enzyme research.

• Sulfo-Cy3 NHS Ester: Advancing Quantitative Vascular Labelin

  2026-04-26

  Explore how Sulfo-Cy3 NHS Ester transforms hydrophilic fluorescent labeling for quantifying vascular remodeling and protein conjugation. This article uniquely bridges technical dye parameters with recent breakthroughs in capillary biology.

• Troglitazone as a PPARγ Agonist: Optimizing Workflows for Me

  2026-04-25

  Troglitazone stands apart as a dual PPARγ/α agonist, enabling precise modulation of lipid and glucose metabolism while opening new avenues for anti-tumor studies. This article translates bench research and reference breakthroughs into actionable protocols, troubleshooting, and cross-validated workflows for both metabolic and cancer biology labs.

• TMEM16F Lipid Scrambling: Ferroptosis Control and Tumor Immu

  2026-04-24

  Yang et al. identified TMEM16F-mediated lipid scrambling as a key suppressor of ferroptosis at the plasma membrane, showing that its inhibition sensitizes tumor cells to ferroptotic death and enhances antitumor immune rejection. This mechanistic insight links membrane lipid dynamics to cancer immunotherapy strategies and may inform future necroptosis and programmed cell death research.

• Reliable cDNA Synthesis for Cell Assays: HyperScript™ K1072

  2026-04-24

  Achieve reproducible results in cell viability and gene expression assays with the HyperScript™ First-Strand cDNA Synthesis Kit (SKU K1072). This article explores scenario-driven challenges and data-backed solutions for low-abundance RNA, complex secondary structures, and vendor reliability—optimizing workflows for biomedical researchers.

• HDAC Inhibition Reverses EBV-Induced Dedifferentiation in NP

  2026-04-23

  This study elucidates how HDAC inhibitors can reverse Epstein-Barr virus (EBV)-induced dedifferentiation and cellular plasticity in nasopharyngeal carcinoma (NPC) by restoring CEBPA expression. The findings introduce an epigenetic mechanism underlying NPC plasticity and propose differentiation therapy as a promising strategy for poorly differentiated solid tumors.

• Redefining Translational Research with 5-moUTP Firefly Lucif

  2026-04-23

  Explore how next-generation Firefly Luciferase mRNA with 5-moUTP modification is transforming translational workflows. This article fuses mechanistic insights, the latest delivery strategies, and authoritative guidance for optimizing mRNA reporter assays, referencing both breakthrough nanoparticle research and hands-on protocol mastery.

• 3-Deazaneplanocin (DZNep): Epigenetic Modulator in Cancer Mo

  2026-04-22

  3-Deazaneplanocin (DZNep) is a potent competitive inhibitor of S-adenosylhomocysteine hydrolase and suppresses the histone methyltransferase EZH2, leading to loss of H3K27 trimethylation. It induces apoptosis and cell cycle inhibitors in acute myeloid leukemia cell lines, and restricts tumorigenicity in hepatocellular carcinoma models. DZNep’s robust activity and protocol flexibility make it a valuable tool in oncology and metabolic disease research.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Interactio

  2026-04-22

  This study reveals that naturally occurring angiotensin peptide fragments, including N-terminally truncated variants, significantly enhance the binding of the SARS-CoV-2 spike protein to its alternative receptor AXL. These findings identify a novel molecular mechanism at the intersection of blood pressure regulation and viral pathogenesis, with implications for both COVID-19 research and renin-angiotensin system modeling.

• EGTA in Endothelial Inflammation: Advanced Calcium Chelation

  2026-04-21

  Explore the specialized use of EGTA (egtaizic acid) as a selective calcium chelator in dissecting endothelial cell inflammation and atherosclerosis. This article uniquely bridges mechanistic insights from recent research with practical assay design, moving beyond traditional neuroprotection paradigms.

• Divergent Effects of Amyloid-β on Human Synapses in Live Bra

  2026-04-21

  This study pioneers real-time investigation of amyloid-β (Aβ) and tau effects on synaptic health using live human brain slice cultures. It reveals distinct synaptic responses to physiological versus pathological Aβ, providing new insights for Alzheimer’s disease research and highlighting critical methodological advances.

• Dabigatran in Thromboembolism: Efficacy, Safety, and Researc

  2026-04-20

  Enriquez et al. (2015) comprehensively reviewed the clinical and pharmacological profile of dabigatran for the prevention and treatment of thromboembolic disorders. This pivotal analysis highlights dabigatran’s advantages over traditional vitamin K antagonists—most notably its predictable pharmacokinetics, reduced monitoring burden, and improved safety profile in key indications such as stroke prevention in atrial fibrillation and venous thromboembolism. The findings inform both clinical and translational research applications.

• Firefly Luciferase mRNA: Redefining Translational Assays

  2026-04-20

  This thought-leadership article explores how EZ Cap™ Firefly Luciferase mRNA (5-moUTP) catalyzes a new era in translational research by integrating advanced chemical modifications with state-of-the-art delivery strategies. Drawing on Yufei Xia’s recent thesis and the latest literature, we dissect mechanistic insights, compare delivery platforms, and provide actionable guidance for researchers aiming to unlock high-fidelity, immune-evading bioluminescent reporter assays.

• Perphenazine: Dopamine D2 Receptor Antagonist in Research Wo

  2026-04-19

  Perphenazine is much more than a classical dopamine D2 receptor antagonist: it offers robust, multi-receptor engagement for both neuropharmacology and host-directed antibacterial assays. Leverage APExBIO's rigorously characterized Perphenazine for mitochondria-mediated cell death studies, opioid tolerance suppression, and advanced immunological research.

15703 records 1/1047 page Next 12345 下5页 Last page